Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome

Sana Sfar, Elham Hassen, Hamadi Saad, Faouzi Mosbah, Lotfi Chouchane

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Objectives: Vascular endothelial growth factor (VEGF) is a potent stimulus of angiogenesis that has an important role in many human malignancies including prostate carcinoma (PCa). We evaluated the role of the functional VEGF polymorphisms as genetic markers for PCa susceptibility and prognosis. Methods: The study included 101 patients with PCa and the 100 age-matched healthy men. The VEGF genotypes -1154G > A were identified by allele-specific polymerase chain reaction (AS-PCR) and the genotypes -634G > C and 936C > T were identified by restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR). Results: A negative association was found between VEGF -1154AA genotype and PCa risk (OR = 0.27; P = 0.009). Furthermore, the presence of the VEGF -1154A allele appeared to be associated with an increased risk of higher tumor grade (OR = 0.37; P = 0.01). A significant increased risk of prostate cancer was associated with the VEGF -634 (GC + CC) combined genotype (OR = 1.95; P = 0.02). The VEGF -634C allele was associated with the aggressive phenotype of prostate cancer as defined by the high histological grade (OR = 3.48; P = 0.007). The VEGF -1154A/-634G haplotype was negatively associated with PCa risk (OR = 0.48; P = 0.005) and high tumor grade compared to low grade (OR = 0.37; P = 0.02). Conclusions: Genetic variations in the VEGF may predict not only PCa risk but also tumor aggressiveness.

Original languageEnglish
Pages (from-to)21-28
Number of pages8
JournalCytokine
Volume35
Issue number1-2
DOIs
Publication statusPublished - Jul 2006
Externally publishedYes

Fingerprint

Genetic Polymorphisms
Polymorphism
Vascular Endothelial Growth Factor A
Prostate
Carcinoma
Genotype
Tumors
Polymerase chain reaction
Alleles
Neoplasms
Prostatic Neoplasms
Polymerase Chain Reaction
Genetic Markers
Restriction Fragment Length Polymorphisms
Haplotypes
Phenotype

Keywords

  • Genetic susceptibility
  • Polymorphism
  • Prognosis
  • Prostate carcinoma
  • VEGF

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Biochemistry
  • Hematology
  • Molecular Biology

Cite this

Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. / Sfar, Sana; Hassen, Elham; Saad, Hamadi; Mosbah, Faouzi; Chouchane, Lotfi.

In: Cytokine, Vol. 35, No. 1-2, 07.2006, p. 21-28.

Research output: Contribution to journalArticle

Sfar, Sana ; Hassen, Elham ; Saad, Hamadi ; Mosbah, Faouzi ; Chouchane, Lotfi. / Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. In: Cytokine. 2006 ; Vol. 35, No. 1-2. pp. 21-28.
@article{a1e90ac7c013414bb86dcf2ad9ac9e27,
title = "Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome",
abstract = "Objectives: Vascular endothelial growth factor (VEGF) is a potent stimulus of angiogenesis that has an important role in many human malignancies including prostate carcinoma (PCa). We evaluated the role of the functional VEGF polymorphisms as genetic markers for PCa susceptibility and prognosis. Methods: The study included 101 patients with PCa and the 100 age-matched healthy men. The VEGF genotypes -1154G > A were identified by allele-specific polymerase chain reaction (AS-PCR) and the genotypes -634G > C and 936C > T were identified by restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR). Results: A negative association was found between VEGF -1154AA genotype and PCa risk (OR = 0.27; P = 0.009). Furthermore, the presence of the VEGF -1154A allele appeared to be associated with an increased risk of higher tumor grade (OR = 0.37; P = 0.01). A significant increased risk of prostate cancer was associated with the VEGF -634 (GC + CC) combined genotype (OR = 1.95; P = 0.02). The VEGF -634C allele was associated with the aggressive phenotype of prostate cancer as defined by the high histological grade (OR = 3.48; P = 0.007). The VEGF -1154A/-634G haplotype was negatively associated with PCa risk (OR = 0.48; P = 0.005) and high tumor grade compared to low grade (OR = 0.37; P = 0.02). Conclusions: Genetic variations in the VEGF may predict not only PCa risk but also tumor aggressiveness.",
keywords = "Genetic susceptibility, Polymorphism, Prognosis, Prostate carcinoma, VEGF",
author = "Sana Sfar and Elham Hassen and Hamadi Saad and Faouzi Mosbah and Lotfi Chouchane",
year = "2006",
month = "7",
doi = "10.1016/j.cyto.2006.07.003",
language = "English",
volume = "35",
pages = "21--28",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press Inc.",
number = "1-2",

}

TY - JOUR

T1 - Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome

AU - Sfar, Sana

AU - Hassen, Elham

AU - Saad, Hamadi

AU - Mosbah, Faouzi

AU - Chouchane, Lotfi

PY - 2006/7

Y1 - 2006/7

N2 - Objectives: Vascular endothelial growth factor (VEGF) is a potent stimulus of angiogenesis that has an important role in many human malignancies including prostate carcinoma (PCa). We evaluated the role of the functional VEGF polymorphisms as genetic markers for PCa susceptibility and prognosis. Methods: The study included 101 patients with PCa and the 100 age-matched healthy men. The VEGF genotypes -1154G > A were identified by allele-specific polymerase chain reaction (AS-PCR) and the genotypes -634G > C and 936C > T were identified by restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR). Results: A negative association was found between VEGF -1154AA genotype and PCa risk (OR = 0.27; P = 0.009). Furthermore, the presence of the VEGF -1154A allele appeared to be associated with an increased risk of higher tumor grade (OR = 0.37; P = 0.01). A significant increased risk of prostate cancer was associated with the VEGF -634 (GC + CC) combined genotype (OR = 1.95; P = 0.02). The VEGF -634C allele was associated with the aggressive phenotype of prostate cancer as defined by the high histological grade (OR = 3.48; P = 0.007). The VEGF -1154A/-634G haplotype was negatively associated with PCa risk (OR = 0.48; P = 0.005) and high tumor grade compared to low grade (OR = 0.37; P = 0.02). Conclusions: Genetic variations in the VEGF may predict not only PCa risk but also tumor aggressiveness.

AB - Objectives: Vascular endothelial growth factor (VEGF) is a potent stimulus of angiogenesis that has an important role in many human malignancies including prostate carcinoma (PCa). We evaluated the role of the functional VEGF polymorphisms as genetic markers for PCa susceptibility and prognosis. Methods: The study included 101 patients with PCa and the 100 age-matched healthy men. The VEGF genotypes -1154G > A were identified by allele-specific polymerase chain reaction (AS-PCR) and the genotypes -634G > C and 936C > T were identified by restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR). Results: A negative association was found between VEGF -1154AA genotype and PCa risk (OR = 0.27; P = 0.009). Furthermore, the presence of the VEGF -1154A allele appeared to be associated with an increased risk of higher tumor grade (OR = 0.37; P = 0.01). A significant increased risk of prostate cancer was associated with the VEGF -634 (GC + CC) combined genotype (OR = 1.95; P = 0.02). The VEGF -634C allele was associated with the aggressive phenotype of prostate cancer as defined by the high histological grade (OR = 3.48; P = 0.007). The VEGF -1154A/-634G haplotype was negatively associated with PCa risk (OR = 0.48; P = 0.005) and high tumor grade compared to low grade (OR = 0.37; P = 0.02). Conclusions: Genetic variations in the VEGF may predict not only PCa risk but also tumor aggressiveness.

KW - Genetic susceptibility

KW - Polymorphism

KW - Prognosis

KW - Prostate carcinoma

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=33749267776&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749267776&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2006.07.003

DO - 10.1016/j.cyto.2006.07.003

M3 - Article

VL - 35

SP - 21

EP - 28

JO - Cytokine

JF - Cytokine

SN - 1043-4666

IS - 1-2

ER -